IP Library Granted Patent US 6,956,112
Granted Patent B2
US 6,956,112 · App. 09/931,232 · Granted Oct 18, 2005

Rapidly degrading GFP-fusion proteins and methods of use

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,956,112
App. No.
09/931,232
Granted
Oct 18, 2005
Kind
B2
Abstract

Green fluorescent protein (GFP) is widely used as a reporter in determining gene expression and protein localization. The present invention provides fusion proteins with a half life of ten hours or less with several embodiments having half lives of 4 hours or less. Such proteins may be constructed by fusing C-terminal amino acids of the degradation domain of mouse ornithine decarboxylase (MODC), which contains a PEST sequence, to the C-terminal end of an enhanced variant of GFP (EGFP). Fluorescence intensity of the fusion protein in transfected cells is similar to that of EGFP, but the fusion protein, unlike EGFP, is unstable in the presence of cycloheximide. Specific mutations in the MODC region have resulted in mutants with varying half lives, useful for a variety of purposes.

Claims (12)

1. An isolated DNA molecule encoding a fusion protein, said fusion protein comprising a fluorescent protein and a PEST sequence, said fusion protein having a half life of no more than about ten hours.

2. The DNA of claim 1 , wherein said isolated DNA encodes a fusion protein wherein said fluorescent protein is selected from the group consisting of enhanced green fluorescent protein (EGFP), enhanced cyan fluorescent protein (ECFP), and enhanced yellow fluorescent protein (EYFP).

3. The isolated DNA of claim 1 , wherein said PEST sequence is a PEST sequence-containing portion of a C-terminus of murine ornithine decarboxylase (MODC) fused to the fluorescent protein.

4. The isolated DNA of claim 3 , wherein said PEST sequence-containing portion of a C-terminus of MODC is selected from the group consisting of MODC.sub.376-461, MODC.sub.376-456 MODC.sub.422 461, P426A/P427A, P438A, E428A/E430A/E431A, E444A, S440A, S445A, T436A, D433A/D434A and D448A.

5. The isolated DNA of claim 3 , having the sequence shown in SEQ ID No: 2.

6. A vector that expresses the isolated DNA molecule of claim 1 .

7. The vector of claim 6 , wherein said vector comprises an inducible promoter.

8. A vector that expresses the isolated DNA molecule of claim 5 .

9. The vector of claim 8 , wherein said vector comprises an inducible promoter.

10. The vector of claim 9 , wherein said promoter is tetracycline-inducible.

11. A method of producing a stable cell line that expresses a fluorescent protein comprising the step of transfecting cells with the vector of claim 6 .

12. The stable cell line produced by the method of claim 11 .

Assignments (2)
CHANGE OF NAME Recorded Aug 4, 2016
From: CLONTECH LABORATORIES, INC.
To: TAKARA BIO USA, INC.
Reel/Frame 039584/0025 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 15, 2001
From: LI, XIANQIANG; KAIN, STEVE
To: CLONTECH LABORATORIES, INC.
Reel/Frame 012102/0788 →